Sangui Biotech International, Inc. Announces Earnings Results for the Second Quarter and Sales Results for the First Six Months of Fiscal Year 2018
February 14, 2018 at 05:07 am EST
Share
Sangui Biotech International, Inc. announced earnings results for the second quarter and sales results for the first six months of fiscal year 2018. For the six months, the company achieved revenues from royalty income and product sales of USD 55,082. In the same period of the previous year the comparable revenue amounted to USD 35,508.
For the second quarter of 2018, the operating loss decreased by USD 96,386 year-on-year to USD 51,336.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
